

HETEROCYCLES, Vol. 99, No. 2, 2019, pp. 1304 - 1314. © 2019 The Japan Institute of Heterocyclic Chemistry
Received, 30th October, 2018, Accepted, 6th December, 2018, Published online, 20th February, 2019
DOI: 10.3987/COM-18-S(F)101

1,2-*cis*-SELECTIVE FORMATION OF A UNIQUE AMINO-CONTAINING AMINO GLYCOSIDE BY ENDOCYCLIC CLEAVAGE STRATEGY

Shino Manabe* and Yukishige Ito*

Synthetic Cellular Chemistry Laboratory, RIKEN, Hirosawa, Wako, Saitama 351-0198, Japan. E-mail: smanabe@riken.jp

Abstract – 2-Acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranoside (AAT), a unique aminated sugar unit, is often found in zwitterionic polysaccharides. Stereoselective formation of the 1,2-*cis* linkage of these unique sugar derivatives was achieved by an anomerization reaction based on an endocyclic cleavage process.

INTRODUCTION

The unusual amino sugar unit, 2-acetamido-4-amino-2,4,6-trideoxy- α -D-galactopyranoside (AAT), is found in bacterial capsular polysaccharide glycans.¹ For example, AAT has been identified in zwitterionic polysaccharides (**1–3**), which are expressed on the capsules of the commensal bacteria *Bacteroides fragilis* and *Streptococcus pneumonia* (Figure 1).^{2,3} It has also been found in type IV lipoteichoic acid (**4**).⁴ The zwitterionic polysaccharides themselves, without conjugated proteins, stimulates CD-4⁺ T-cell proliferation after being presented via the MHC-II processing pathway,⁵ and also stimulates the innate immune system through interaction with the Toll-like receptor 2.⁶ In connection with their biological activities, several attempts to synthesize zwitterionic polysaccharides have been reported.⁷⁻¹⁰ One of the key features necessary for AAT-containing polysaccharide synthesis is construction of the 1,2-*cis* linkage. The 1,2-*cis*-selective glycosylation reaction of amino sugars is difficult; 2-azido-2-deoxy sugars have been used in the most cases.¹¹ Furthermore, because AAT contains two amino groups, differentiation between them is essential for efficient zwitterionic glycan synthesis. For these reasons, the design of AAT-related glycosyl donors has been complicated. To overcome these difficulties, several approaches have been reported, including *de novo* synthesis.^{8,12-15}





Figure 1. AAT-containing oligosaccharides

Previously, we reported that anomerization easily occurred under weak Lewis acidic conditions when an *N*-acetyl 2,3-*trans* carbamate group was installed in 2-amino-2-deoxy pyranosides.¹⁶ The anomerization reaction gives the 1,2-*cis*-anomer from the 1,2-*trans*-anomer through an endocyclic cleavage reaction, in which the bond between the anomeric carbon and the ring oxygen (O5) is cleaved. After cleavage, recyclization of the linear cation gives the 1,2-*cis* glycoside with extremely high selectivity. Based on these results, we expected that the endocyclic cleavage reaction would be advantageous for 1,2-*cis* AAT formation in two ways. First, the 1,2-*cis* linkage would be created by endocyclic cleavage-mediated anomerization with extremely high selectivity. Second, the differential protecting groups from our previous examples could be used for the 2- and 4-amino groups.


We applied our endocyclic cleavage reaction to the synthesis of AAT via the strategy shown in Scheme 1. First, from the glucosamine derivative **5**, the two amino groups are introduced/protected as the azide and phthalimide groups in **6**. Then, the 1,2-*trans* glycoside can be prepared using the phthalimide neighboring-participation effect. After the removal of phthalimide and acetyl group, the *N*-acetyl 2,3-*trans* carbamate group is introduced. Then, with treatment of the 1,2-*trans* glycoside under Lewis acidic conditions, the desired 1,2-*cis* glycoside is obtained.



Scheme 1. 1,2-*cis* AAT formation via anomerization through an endocyclic cleavage reaction


RESULTS AND DISCUSSION

The glycosyl donor was prepared as shown in Scheme 2. Tosylation of diol **5** gave mono-tosylate **7** and di-tosylate **11** in 80% and 7% yield, respectively. Treatment of tosylates **7** and **11** with NaI displaced the primary tosyl group to afford iodides **8** and **12** both in quantitative yields. Zn reduction of iodide **8** afforded 6-deoxy compound **9** in 70% yield. After triflation and azide substitution, donor **6** was obtained in 72% yield. Because of the low solubility and reactivities of **12** and **13**, yields of reduction and substitution reaction were low. From **12**, **6** was obtained in 46% yield over two steps.



Scheme 2. Glycosyl donor preparation from the diol **5**

The glycosylation reaction between donor **6** and acceptor **14** was carried out under typical glycosylation conditions for thioglycosides, using NIS-TMSOTf (Scheme 3). The 1,2-*trans* glycoside **15** was obtained in 89% yield, and the 1,2-*trans* linkage was confirmed from the ^1H NMR coupling constant ($J = 8.8$ Hz) of the anomeric position. After simultaneous removal of the phthalimide and acetyl groups by ethylenediamine, a 2,3-*trans* carbamate group was installed with triphosgene. *N*-Acetylation of the carbamate group was achieved with Ac_2O -pyridine in the presence of DMAP. The 1,2-*trans* glycoside **18** was quantitatively anomerized to give **19** in the presence of $\text{BF}_3 \cdot \text{OEt}_2$ at -30 °C. The 1,2-*cis* configuration of anomeric position was confirmed by ^1H NMR coupling constant ($J = 2.8$ Hz).



Scheme 3. Glycosylation and anomerization through endocyclic cleavage reaction

In conclusion, we have demonstrated that our anomerization strategy is useful for the 1,2-*cis*-selective synthesis of amino sugar units. Although we have only reported a model study in this paper, our strategy could be generalized to the synthesis of zwitterionic polysaccharides in the future.

EXPERIMENTAL

^1H NMR spectra were recorded with AL 400 spectrometer (JEOL) at ambient temperatures (24–26 °C). Chemical shifts (δ) are reported in ppm relative to remaining solvent peak CDCl_3 ($\delta = 7.26$ ppm) for ^1H NMR spectra. ^{13}C NMR chemical shifts (δ) are reported in ppm relative to CDCl_3 ($\delta = 77.00$ ppm). Optical rotations were measured at room temperature (JASCO DIP-310). All commercial reagents were used without further purification. Analytical TLC was performed on silica gel 60 F254 plates (Merck) and visualized by UV fluorescence quenching and 12 Molybdo(VI) phosphoric acid acid/phosphoric acid/sulfuric acid staining. Flash column chromatography was performed on silica gel 60N (spherical, neutral, 40–100 μm , Kanto Co.). Yields reported here are isolated yields.

Phenyl 3-*O*-acetyl-2-deoxy-4,6-*O*-isopropylidene-2-phthalimido-1-thio- β -D-glucopyranoside

Phenyl 3-*O*-acetyl-4,6-*O*-isopropylidene-2-deoxy-2-phthalimido-1-thio- β -D-glucopyranoside¹⁷ (1.45 g, 3.29 mmol) was dissolved in pyridine (10 mL), and Ac_2O (5 mL) was added. After stirring the mixture overnight, the mixture was concentrated. The residue was purified by silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give 1.56 g (98%) of acetate. ^1H NMR (400 MHz, CDCl_3) δ 7.86 (m, 2H), 7.76-7.74 (m, 2H), 7.37-7.36 (m, 2H), 7.27-7.26 (m, 3H), 5.78 (d, $J = 10.4$ Hz, 1H), 5.70 (t, $J = 9.2$ Hz, 1H), 4.29 (t, $J = 10.0$ Hz, 1H), 4.03 (dd, $J = 10.8$ Hz, 5.2 Hz, 1H), 3.86-3.77 (m, 2H), 3.65-3.61 (m, 1H),

1.88 (s, 3H), 1.49 (s, 3H), 1.38 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 167.8, 167.3, 134.4, 134.2, 132.9, 131.7, 131.3, 131.2, 129.0, 128.2, 123.7, 99.8, 83.8, 71.8, 71.6, 71.0, 62.0, 54.3, 28.9, 20.6, 19.0. $[\alpha] +29.4$ (*c* 1.2, CHCl_3). HRMS calcd for $[\text{C}_{25}\text{H}_{25}\text{NO}_7\text{S}+\text{Na}]^+$ 506.1244; found 506.1257.

Phenyl 3-*O*-acetyl-2-deoxy-2-phthalimido-1-thio- β -D-glucopyranoside (5)

A mixture of acetal (1.56 g, 3.22 mmol) in trifluoroacetic acid (1 mL), H_2O (0.25 mL), and CH_2Cl_2 (10 mL) was stirred at room temperature for 2 h. After concentration, the mixture was washed with Et_2O -hexane to give diol **5** (1.28 g, 90%). The diol **5** was used for the next reaction without further purification. ^1H NMR (400 MHz, CDCl_3) δ 7.87 (m, 2H), 7.76-7.75 (m, 2H), 7.39-7.37 (m, 2H), 7.27-7.17 (m, 3H), 5.76 (d, *J* = 10.8 Hz, 1H), 5.66 (t, *J* = 9.2 Hz, 1H), 4.30 (t, *J* = 10.8 Hz, 1H), 4.00 (dd, *J* = 15.2 Hz, 3.2 Hz, 1H), 3.87 (dd, *J* = 15.2 Hz, 4.4 Hz, 1H), 3.81 (t, *J* = 9.6 Hz, 1H), 3.68 (m, 1H), 1.93 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.4, 134.5, 134.3, 122.7, 131.5, 131.4, 129.0, 128.2, 123.7, 83.1, 79.6, 74.5, 69.9, 62.4, 53.7, 20.7. $[\alpha] +41.4$ (*c* 0.5, CHCl_3). HRMS calcd for $[\text{C}_{22}\text{H}_{21}\text{NO}_7\text{S}+\text{Na}]^+$ 466.0931; found 466.0926.

Phenyl 3-*O*-acetyl-2-deoxy-2-phthalimido-1-thio-6-*O*-(4-toluenesulfonyl)- β -D-glucopyranoside (7)

To a solution of diol **5** (1.56 g, 3.52 mmol) in pyridine (20 mL), TsCl (1.34 g, 7.04 mmol) was added at room temperature in several portions. After overnight, pyridine was evaporated, and the residue was diluted with CHCl_3 and 1 M HCl. The aqueous layer was washed with CHCl_3 and the combined layers were washed with brine. After drying the mixture over Na_2SO_4 and evaporation, the residue was purified by silica gel column chromatography (hexane:EtOAc 4:1-1:1) to give compound **7** (1.68 g, 80%) and **11** (185 mg, 7%). ^1H NMR (400 MHz, CDCl_3) δ 7.86-7.76 (m, 6H), 7.36-7.33 (m, 4H), 7.26-7.20 (m, 3H), 5.70 (d, *J* = 10.8 Hz, 1H), 5.65 (t, *J* = 9.6 Hz, 1H), 4.41-4.36 (m, 2H), 4.23 (t, *J* = 10.8 Hz, 1H), 3.77 (m, 1H), 3.71 (m, 1H), 2.92 (bs, 1H), 2.44 (s, 3H), 1.91 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.3, 145.1, 134.3, 132.9, 132.7, 131.2, 129.9, 128.9, 128.2, 128.1, 123.7, 83.0, 77.5, 74.1, 69.0, 68.4, 53.3, 21.7, 20.6. $[\alpha] +29.8$ (*c* 0.98, CHCl_3). HRMS calcd for $[\text{C}_{29}\text{H}_{27}\text{NO}_9\text{S}_2+\text{Na}]^+$ 620.1019; found 620.1103.

Phenyl 3-*O*-acetyl-2-deoxy-2-phthalimido-1-thio-4,6-di-*O*-(4-toluenesulfonyl)- β -D-glucopyranoside (11)

^1H NMR (400 MHz, CDCl_3) δ 7.86-7.72 (m, 10H), 7.35-7.24 (m, 7H), 5.78 (t, *J* = 8.8 Hz, 1H), 5.58 (d, *J* = 10.4 Hz, 1H), 4.68 (t, *J* = 9.2 Hz, 1H), 4.34 (d, *J* = 11.2 Hz, 1H), 4.24 (t, *J* = 10.0 Hz, 1H), 4.03 (dd, *J* = 11.2, 6.0 Hz, 1H), 3.81 (m, 1H), 2.44 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.0, 167.6, 166.8, 145.5, 145.1, 134.5, 133.3, 133.2, 132.7, 131.5, 130.4, 129.9, 129.0, 128.5, 128.2, 128.1, 127.7, 123.7, 100.5, 82.8, 75.4, 74.6, 70.7, 67.5, 21.7, 20.2. $[\alpha] +30.3$ (*c* 0.61, CHCl_3). HRMS calcd for $[\text{C}_{35}\text{H}_{11}\text{NO}_{11}\text{S}_3+\text{Na}]^+$ 760.0951; found 760.0973.

Phenyl 3-*O*-acetyl-2,6-dideoxy-6-iodo-2-phthalimido-1-thio- β -D-glucopyranoside (8)

A suspension of tosylate **7** (955 mg, 1.60 mmol) and NaI (400 mg, 1.26 mmol) in 2-butanone (30 mL), was stirred at 80 °C overnight. After cooling the mixture to room temperature, sat. aq. NaHCO₃ was added. The aqueous layer was extracted with EtOAc several times. The combined layers were washed with brine and dried over Na₂SO₄. After filtration and concentration, the mixture was purified by silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give iodide **8** (850 mg, quant.). ¹H NMR (400 MHz, CDCl₃) δ 7.87 (m, 2H), 7.78-7.76 (m, 2H), 7.51-7.49 (m, 2H), 7.29-7.26 (m, 3H), 5.74 (d, *J* = 10.4 Hz, 1H), 5.65 (t, *J* = 9.6 Hz, 1H), 4.28 (t, *J* = 10.8 Hz, 1H), 3.68-3.59 (m, 2H), 3.48-3.41 (m, 2H), 2.66 (d, *J* = 5.2 Hz, 1H), 1.92 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.6, 134.5, 133.7, 130.7, 128.9, 128.4, 123.7, 82.7, 78.2, 74.4, 73.5, 53.4, 20.6, 5.8. [α] +19.2 (*c* 0.62, CHCl₃). HRMS calcd for [C₂₂H₂₀NO₆IS+Na]⁺ 575.9948. found 575.9945.

Phenyl 3-*O*-acetyl-2,6-dideoxy-6-iodo-2-phthalimido-1-thio-4-*O*-(4-toluenesulfonyl)-β-D-glucopyranoside (12)

A suspension of tosylate **11** (0.23 g, 0.306 mmol) and NaI (56 mg, 0.380 mmol) in 2-butanone (5 mL), was stirred at 80 °C. After overnight, the mixture was diluted with EtOAc and sat. aq. NaHCO₃ was added. After extracted with EtOAc several times, the combined layers were washed with brine. After drying over Na₂SO₄ and concentration, the residue was washed with ether-hexane to give iodide **12** (66 mg, quant.).

¹H NMR (400 MHz, CDCl₃) δ 7.87-7.85 (m, 2H), 7.77-7.74 (m, 4H), 7.51-7.50 (m, 2H), 7.34-7.29 (m, 5H), 5.82 (t, *J* = 9.2 Hz, 1H), 5.72 (d, *J* = 10.4 Hz, 1H), 4.67 (t, *J* = 9.2 Hz, 1H), 4.28 (t, *J* = 10.8 Hz, 1H), 3.60 (m, 1H), 3.53 (dd, *J* = 12.8 Hz, 2.4 Hz, 1H), 3.19 (dd, *J* = 11.2 Hz, 7.2 Hz, 1H), 2.43 (s, 3H), 1.59 (s, 3H). ¹³C NMR (400 MHz, CDCl₃) δ 170.0, 145.3, 134.5, 134.0, 133.6, 130.1, 130.0, 128.9, 128.7, 127.7, 127.6, 123.7, 82.8, 78.8, 76.7, 70.4, 53.8, 21.6, 20.1, 3.6. [α] 25.7 (*c* 0.47, CHCl₃). HRMS calcd for [C₂₉H₂₆NO₈S₂+Na]⁺ 730.0037. found 730.0045.

Phenyl 3-*O*-acetyl-2,6-dideoxy-2-phthalimido-1-thio-β-D-glucopyranoside (9)

To a solution of iodide **8** (0.85 g, 1.54 mmol) in AcOH (2 mL) and CH₂Cl₂ (20 mL), Zn (5 g) was added at room temperature. After stirring the mixture for 2 h, Zn was filtered through celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give 0.46 g (70%) of iodide **9**. ¹H NMR (400 MHz, CDCl₃) δ 7.86-7.78 (m, 2H), 7.76-7.74 (m, 2H), 7.40-7.38 (m, 2H), 7.26-7.25 (m, 3H), 5.71 (d, *J* = 10.8 Hz, 1H), 5.60 (t, *J* = 10.4 Hz, 1H), 4.30 (t, *J* = 10.8 Hz, 1H), 3.66 (m, 1H), 3.43 (m, 1H), 2.44 (bs, 1H), 1.90 (s, 3H), 1.43 (d, *J* = 6.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 171.5, 134.4, 134.2, 132.7, 128.9, 128.0, 123.6, 82.9, 76.4, 74.9, 74.8, 53.9, 20.7, 17.9. [α] +45.7 (*c* 0.53, CHCl₃). HRMS calcd for [C₂₂H₂₁NO₆S+Na]⁺ 450.0982. found 450.0976.

Phenyl 3-*O*-acetyl-2,6-dideoxy-2-phthalimido-1-thio-4-*O*-(4-toluenesulfonyl)- β -D-glucopyranoside (13)

From **9**) To a mixture of alcohol (0.46 g, 0.771 mmol) in pyridine (10 mL), TsCl (409 mg, 2.15 mmol) was added. The mixture was stirred at room temperature for 3 h, then, warmed at 70 °C. After overnight, the mixture was concentrated. The residue was dissolved in CHCl₃ and 1 M HCl. The aqueous layer was extracted with CHCl₃ and the combined layers were washed with brine. After drying over Na₂SO₄, the solvent was removed *in vacuo*. The residue was purified by silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give 0.32 g (55%) of tosylate **13**.

From **12**) To a solution of iodide **12** (0.20 g, 0.266 mmol) in AcOH (1 mL) and CH₂Cl₂ (10 mL), Zn (1 g) was added at room temperature. After stirring the mixture for 2 h, Zn was filtered through celite, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give 99 mg (64%) of tosylate **13**. ¹H NMR (400 MHz, CDCl₃) δ 7.86-7.84 (m, 2H), 7.86-7.74 (m, 4H), 7.39-7.37 (m, 2H), 7.32-7.23 (m, 5H), 5.78 (t, *J* = 10.4 Hz, 1H), 5.67 (d, *J* = 10.8 Hz, 1H), 4.55 (t, *J* = 9.2 Hz, 1H), 4.28 (t, *J* = 10.0 Hz, 1H), 3.77 (m, 1H), 2.42 (s, 3H), 1.83 (s, 3H), 1.35 (d, *J* = 6.4 Hz, 3H). [α] +22.1 (*c* 0.29, CHCl₃). HRMS calcd for [C₃₀H₂₉NO₇S₂+Na]⁺ 602.1278; found 602.1285.

Phenyl 3-*O*-acetyl-2,6-dideoxy-2-phthalimido-1-thio-4-*O*-trifluoromethanesulfonyl- β -D-glucopyranoside (10)

To a mixture of alcohol (0.47 g, 0.787 mmol) in pyridine (1 mL) and CH₂Cl₂ (10 mL), Tf₂O (0.26 mL, 1.57 mmol) was added at -20 °C. The mixture was stirred at -20 °C for 30 min, then 1 M HCl and EtOAc were added. The aqueous layer was extracted with EtOAc and the combined layers were washed with brine. After drying over Na₂SO₄, the solvent was removed *in vacuo*. The residue was purified by silica gel column chromatography (hexane:EtOAc 7:3) to give 0.41 g of triflate **10** (72%). ¹H NMR (400 MHz, CDCl₃) δ 7.89-7.88 (m, 2H), 7.78-7.76 (m, 2H), 7.40-7.26 (m, 5H), 5.88 (t, *J* = 9.2 Hz, 1H), 5.74 (d, *J* = 10.8 Hz, 1H), 4.66 (t, *J* = 9.2 Hz, 1H), 4.31 (t, *J* = 10.0 Hz, 1H), 3.93 (m, 1H), 1.91 (s, 3H), 1.48 (d, *J* = 6.3 Hz, 3H). [α] +28.1 (*c* 0.41, CHCl₃).

Phenyl 3-*O*-acetyl-4-azido-2,4,6-trideoxy-2-phthalimido-1-thio- β -D-glucopyranoside (6)

Method A) To a mixture of tosylate (0.32 g, 0.550 mmol) in DMF (3 mL), NaN₃ (0.15 g, 2.31 mmol) was added. The mixture was stirred at 120 °C overnight. After cooling the mixture to room temperature, the mixture was diluted with EtOAc and sat. aq. NaHCO₃. The aqueous layer was extracted with EtOAc. The combined layers were washed with brine, and dried over Na₂SO₄. After concentration, the residue was purified by silica gel column chromatography (hexane:EtOAc 7:3) to give 0.18 g (72%) of product **6**.

Method B) A mixture of triflate (0.41 g, 0.733 mmol) in DMF (3 mL), NaN₃ (0.15 g, 2.31 mmol) was added. The mixture was stirred at 40 °C overnight. After cooling the mixture to room temperature, the mixture was diluted with EtOAc and sat. aq. NaHCO₃. The aqueous layer was extracted with EtOAc. The

combined layers were washed with brine, and dried over Na₂SO₄. After concentration, the residue was purified by silica gel column chromatography (hexane:EtOAc 7:3) to give 0.33 g of product **6** (quant.).

¹H NMR (400 MHz, CDCl₃) δ 7.90-7.75 (m, 4H), 7.40-7.37 (m, 2H), 7.26-7.24 (m, 3H), 5.84 (dd, *J* = 10.8 Hz, 4.0 Hz, 1H), 5.61 (d, *J* = 10.8 Hz, 1H), 4.65 (t, *J* = 10.4 Hz, 1H), 3.98-3.93 (m, 2H), 1.96 (s, 3H), 1.41 (d, *J* = 6.0 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 170.0, 168.1, 167.1, 134.3, 132.6, 131.9, 131.6, 131.3, 128.9, 128.0, 123.8, 123.6, 83.6, 73.4, 71.4, 63.6, 50.0, 20.4, 17.8. HRMS calcd for [C₂₂H₂₀N₄O₅S+Na]⁺ 475.1047; found 475.1057.

Methyl (3-*O*-acetyl-2-amino-4-azido-2,4,6-trideoxy-2-phthalimido-β-D-glucopyranosyl)-(1 → 4)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (15)

To a suspension of acceptor **14** (145 mg, 0.313 mmol), donor **6** (184 mg, 0.407 mmol), and NIS (101 mg, 0.448 mmol) in CH₂Cl₂ (3 mL), TMSOTf (10 μL, 0.0448 mmol) was added at -40 °C under Ar atmosphere. After 30 min, the reaction was quenched with 10% Na₂S₂O₃, and the aqueous layer was extracted with EtOAc. The combined layers were washed with sat. aq. NaHCO₃ and brine. After during over Na₂SO₄, the solvent was removed under reduced pressure. The residue was purified by gel filtration (SX-4, toluene) and silica gel column chromatography (hexane:EtOAc 7:3-1:1) to give 224 mg (89%) of disaccharide **15**. ¹H NMR (400 MHz, CDCl₃) δ 7.79 (d, *J* = 7.6 Hz, 1H), 7.61-7.57 (m, 3H), 7.30-7.07 (m, 15 H), 7.08-7.07 (m, 2H), 5.80 (dd, *J* = 11.6 Hz, 4.0 Hz, 1H), 5.23 (d, *J* = 8.8 Hz, 1H), 4.86 (d, *J* = 11.2 Hz, 1H), 4.72-4.55 (m, 4H), 4.47 (d, *J* = 10.8 Hz, 1H), 4.32 (d, *J* = 3.6 Hz, 1H), 4.20 (d, *J* = 10.8 Hz, 1H), 4.05 (d, *J* = 8.8 Hz, 1H), 3.95 (d, *J* = 2.8 Hz, 1H), 3.89-3.82 (m, 2H), 3.62 (m, 1H), 3.56 (dd, *J* = 10.0 Hz, 5.2 Hz, 1H), 3.35 (dd, *J* = 9.6 Hz, 3.2 Hz, 1H), 3.21 (t, *J* = 9.2 Hz, 1H), 3.12 (s, 3H), 1.97 (s, 3H), 1.38 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 175.3, 170.1, 168.4, 167.2, 138.7, 138.1, 137.9, 134.1, 131.4, 131.3, 128.4, 128.3, 128.0, 127.9, 127.7, 127.5, 123.5, 123.3, 98.4, 97.6, 81.8, 79.7, 77.8, 75.6, 74.7, 73.3, 7.6, 69.3, 69.2, 68.3, 63.3, 54.8, 51.1, 20.4, 17.4. [α] -17.9 (*c* 0.43, CHCl₃). HRMS calcd for [C₂₂H₂₀N₄O₅S+Na]⁺ 475.1047; found 475.1056.

Methyl (2-amino-4-azido-2,4,6-trideoxy-β-D-glucopyranosyl)-(1 → 4)-2,3,4-tri-*O*-benzyl-α-D-glucopyranoside (16)

A solution of compound **15** (278 mg, 0.345 mmol) and ethylenediamine (0.2 mL) in DMF (1 mL) was stirred at 100 °C under Ar atmosphere overnight. After concentration, the residue was purified by silica gel column chromatography (CHCl₃:MeOH 9:1) to 180 mg of amino alcohol **16** (87%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.26 (m, 15H), 4.99 (d, *J* = 10.8 Hz, 1H), 4.90 (d, *J* = 11.2 Hz, 1H), 4.80 (d, *J* = 10.8 Hz, 1H), 4.79 (d, *J* = 12.4 Hz, 1H), 4.66 (d, *J* = 12.4 Hz, 1H), 4.66-4.58 (m, 2H), 4.07 (d, *J* = 9.6 Hz, 1H), 4.00 (t, *J* = 9.2 Hz, 1H), 3.94 (d, *J* = 7.6 Hz, 1H), 3.82 (m, 1H), 3.82 (m, 1H), 3.62-3.41 (m, 15H), 3.38 (s, 3H), 3.32 (t, *J* = 5.6 Hz, 1H), 2.84 (t, *J* = 7.6 Hz, 1H), 1.33 (d, *J* = 6.4 Hz, 3H). ¹³C

NMR (100 MHz, CDCl₃) δ 138.6, 138.3, 138.1, 128.4, 128.1, 128.0, 127.9, 127.7, 104.8, 97.9, 82.0, 79.8, 78.0, 77.2, 75.8, 74.8, 74.2, 73.3, 69.8, 69.7, 68.2, 65.9, 55.2, 54.0, 17.6. $[\alpha]$ +4.2 (*c* 0.92, CHCl₃). HRMS calcd for [C₃₄H₄₂N₄O₈+H]⁺ 635.3075. found 635.3066.

Methyl (2-amino-4-azido-2,3-*N,O*-carbonyl-2,4,6-trideoxy- β -D-glucopyranosyl)-(1 \rightarrow 4)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (17)

To a solution of amino alcohol **16** (159 mg, 0.251 mmol) in MeCN (2 mL) and sat. aq. NaHCO₃ (0.5 mL), triphosgene (222 mg, 0.75 mmol) was added at 4 °C. After stirring the mixture at room temperature overnight, the mixture was acidified with 1 M HCl, and the aqueous layer was extracted with CHCl₃. The combined layers were washed with brine, and dried over Na₂SO₄. After concentration, the residue was purified by silica gel column chromatography (CHCl₃:EtOAc 7:3-1:1) to give 135 mg of carbamate **17** (81%).

¹H NMR (400 MHz, CDCl₃) δ 7.34-7.25 (m, 15H), 5.17 (bs, 1H), 5.00 (d, *J* = 11.2 Hz, 1H), 4.91 (d, *J* = 11.2 Hz, 1H), 4.80 (d, *J* = 11.2 Hz, 1H), 4.79 (d, *J* = 11.2 Hz, 1H), 4.66 (d, *J* = 12.4 Hz, 1H), 4.58-4.52 (m, 2H), 4.29 (d, *J* = 7.6 Hz, 1H), 4.10 (dd, *J* = 11.6 Hz, 2.8 Hz, 1H), 4.02-3.97 (m, 2H), 3.89 (bs, 1H), 3.80-3.86 (m, 3H), 3.72-3.70 (m, 1H), 3.62 (dd, *J* = 11.2 Hz, 5.2 Hz, 1H), 3.51 (dd, *J* = 9.2 Hz, 3.6 Hz, 1H), 3.41 (t, *J* = 9.6 Hz, 1H), 3.37 (s, 3H), 1.34 (d, *J* = 5.6 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.3, 138.5, 138.2, 138.0, 128.5, 128.2, 128.0, 127.7, 102.1, 98.1, 81.9, 79.7, 77.7, 75.8, 74.9, 73.4, 71.9, 69.6, 68.0, 60.5, 55.5, 55.3, 17.2. $[\alpha]$ +8.1 (*c* 0.37, CHCl₃). HRMS calcd for [C₃₅H₄₀N₄O₉+H]⁺ 683.2688. found 661.2865.

Methyl (*N*-acetyl-2-amino-4-azido-2,3-*N,O*-carbonyl-2,4,6-trideoxy- β -D-glucopyranosyl)-(1 \rightarrow 4)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (18)

To a solution of carbamate **17** (230.5 mg, 0.349 mmol) in pyridine (3 mL), Ac₂O (2 mL) and DMAP (10 mg) were added. After 2 h, the mixture was concentrated, and the residue was dissolved in CHCl₃, and the organic layer was washed with 1 M HCl and brine. After drying over Na₂SO₄ and concentration, the residue was purified by silica gel column chromatography (CHCl₃:EtOAc 4:1-7:3) to give 183.6 mg of *N*-acetyl carbamate **18** (75%). ¹H NMR (400 MHz, CDCl₃) δ 7.35-7.23 (m, 15H), 4.99 (d, *J* = 10.8 Hz, 1H), 4.86 (d, *J* = 11.2 Hz, 1H), 4.81-4.78 (m, 2H), 4.67 (d, *J* = 12.0 Hz, 1H), 4.62 (d, *J* = 3.6 Hz, 1H), 4.56 (d, *J* = 11.2 Hz, 1H), 4.44 (d, *J* = 7.6 Hz, 1H), 4.21 (t, *J* = 11.6 Hz, 1H), 4.12 (bs, 1H), 4.08 (m, 1H), 4.05 (m, 1H), 3.99 (t, *J* = 10.0 Hz, 1H), 3.95 (m, 1H), 3.97-3.95 (m, 2H), 3.67 (dd, *J* = 10.8 Hz, 4.4 Hz, 1H), 3.59-3.53 (m, 2H), 3.38 (s, 3H), 2.46 (s, 3H), 1.32 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 153.5, 138.8, 138.7, 138.2, 128.4, 128.4, 128.1, 128.0, 127.6, 102.2, 98.0, 82.2, 80.0, 77.7, 77.5,

75.6, 74.5, 73.4, 71.6, 69.7, 66.8, 60.2, 56.6, 55.2, 25.0, 24.9, 17.2. $[\alpha] -31.2$ (c 0.84, CHCl_3). HRMS calcd for $[\text{C}_{37}\text{H}_{42}\text{N}_4\text{O}_{10}+\text{H}]^+$ 703.2973. found 703.2974.

Methyl (*N*-acetyl-2-amino-4-azido-2,3-*N,O*-carbonyl-2,4,6-trideoxy- α -D-glucopyranosyl)-(1 \rightarrow 4)-2,3,4-tri-*O*-benzyl- α -D-glucopyranoside (19)

To a solution of 1,2-*trans* glycoside **18** (123.0 mg, 0.175 mmol) in MeCN (2 mL), $\text{BF}_3 \cdot \text{OEt}_2$ (11 μL , 0.088 mmol) was dropped at -30 °C. After 2 h, the reaction was quenched with Et_3N , then mixture was diluted with CHCl_3 and sat. aq. NaHCO_3 . After extraction of the aqueous layer with CHCl_3 several times, the combined layers were washed with brine. After drying the extract over Na_2SO_4 , the solvent was removed *in vacuo*. The residue was purified by preparative TLC (hexane:EtOAc 7:3) to give 1,2-*cis* glycoside **19** (122.8 mg, quant.). ^1H NMR (400 MHz, CDCl_3) δ 7.37-7.23 (m, 15H), 5.65 (d, $J = 2.8$ Hz, 1H), 5.00 (d, $J = 10.8$ Hz, 1H), 4.85-4.66 (m, 3H), 4.58 (d, $J = 9.2$ Hz, 1H), 4.56-4.54 (m, 3H), 4.12 (dd, $J = 12.4$ Hz, 2.8 Hz, 1H), 4.00-3.93 (m, 3H), 3.74-3.67 (m, 3H), 3.51 (dd, $J = 9.6$ Hz, 3.6 Hz, 1H), 3.34 (s, 3H), 3.30-3.28 (m, 1H), 2.41 (s, 3H), 1.26 (d, $J = 6.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 171.1, 152.7, 138.7, 138.0, 128.4, 128.4, 128.4, 128.1, 127.9, 127.9, 127.8, 127.6, 97.8, 96.1, 81.9, 79.8, 77.2, 75.5, 74.6, 73.6, 73.2, 69.9, 67.0, 66.8, 61.8, 55.6, 55.1, 23.7, 17.1. $[\alpha] -73.2$ (c 1.0, CHCl_3). HRMS calcd for $[\text{C}_{37}\text{H}_{42}\text{N}_4\text{O}_{10}+\text{H}]^+$ 703.2973. found 703.2974.

ACKNOWLEDGEMENTS

We thank thanks Dr. Kaori Otsuki, Dr. Masaya Usui, and Dr. Aya Abe of the Research Resource Center at the Brain Science Center, RIKEN for help with the HRMS measurements, and Ms. Akemi Takahashi for technical assistance.

REFERENCES

1. B. Lindberg, B. Lindqvist, J. Lönnngren, and D. A. Powell, *Carbohydr. Res.*, 1980, **78**, 111.
2. H. Baumann, A. O. Tzianabos, J.-R. Brisson, D. L. Kasper, and H. J. Jennings, *Biochemistry*, 1992, **31**, 4081.
3. Y.-H. Choi, M. H. Roehrl, D. L. Kasper, and J. Y. Wang, *Biochemistry*, 2002, **41**, 15144.
4. J. W. Greenberg, W. Fisher, and K. A. Joiner, *Infect. Immun.*, 1996, **64**, 3318.
5. J. Duan, F. Y. Avci, and D. L. Kasper, *Proc. Natl. Acad. Sci. U.S.A.*, 2008, **105**, 5183.
6. Q. Wang, R. M. McLoughlin, B. A. Cobb, M. Charrel-Dennis, K. J. Zaleski, D. Golenbock, A. O. Tianabos, and D. L. Kasper, *J. Exp. Med.*, 2006, **203**, 2863.
7. X. Wu, L. Cui, T. Lipinski, and D. R. Bundle, *Chem. Eur. J.*, 2010, **16**, 3476.

8. R. Pragani and P. H. Seeberger, *J. Am. Chem. Soc.*, 2011, **133**, 102.
9. A. E. Cristina, L. J. van den Bos, H. S. Overkleeft, G. A. van der Marel, and J. D. C. Codée, *J. Org. Chem.*, 2011, **76**, 1692.
10. A. N. Cheallaigh and S. Oscarson, *Can. J. Chem.*, 2016, **94**, 940.
11. G. Ngoje and Z. Li, *Org. Biomol. Chem.*, 2013, **11**, 1879, and references therein.
12. P. Smid, W. P. A. Jorning, A. M. G. van Duuren, G. J. P. H. Boons, G. A. van der Marel, and J. H. van Boom, *J. Carbohydr. Chem.*, 1992, **11**, 849.
13. L. J. van den Bos, T. J. Boltje, T. Provoost, J. Mazurek, H. S. Overkleeft, and G. A. van der Marel, *Tetrahedron Lett.*, 2007, **48**, 2697.
14. H. B. Pfister and L. A. Mulard, *Org. Lett.*, 2014, **16**, 4892.
15. A. Chaudhury and R. Ghosh, *Org. Biomol. Chem.*, 2017, **15**, 1444.
16. S. Manabe and Y. Ito, *Pure Appl. Chem.*, 2017, **89**, 899.
17. W. Zou and H. J. Jennings, *J. Carbohydr. Chem.*, 1996, **15**, 279.